The association of serum prolidase activity with the presence and severity of coronary artery disease

Coronary Artery Disease

Volumn 19, Issue 5, 2008, Pages 319-325

  Yildiz, Ali ^a   Demirbag, Recep ^a   Yilmaz, Remzi ^a   Gur, Mustafa ^a   Altiparmak, Ibrahim H ^a   Akyol, Selahattin ^a   Aksoy, Nurten ^a   Ocak, Ali R ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Collagen turnover; Extracellular matrix; Oxidative stress; Prolidase activity

Indexed keywords

FERROUS ION; LIPID HYDROPEROXIDE; PROLINE DIPEPTIDASE; THIOL DERIVATIVE; BIOLOGICAL MARKER; DIPEPTIDASE; LIPID PEROXIDE;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; AGED; ANALYSIS OF VARIANCE; ANGIOCARDIOGRAPHY; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; HOSPITALIZATION; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; RADIOGRAPHY; SERUM; STATISTICAL MODEL;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIPEPTIDASES; FEMALE; HUMANS; LINEAR MODELS; LIPID PEROXIDES; MALE; MIDDLE AGED; OXIDATIVE STRESS; SERUM; SEVERITY OF ILLNESS INDEX;

EID: 58149117667     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32830042ba     Document Type: Article

References (41)

1. Palka JA, Phang JM. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem 1997; 67:166-175.
2. Zanaboni G, Dyne KM, Rossi A, Monafo V, Cetta G. Prolidase deficiency: biochemical study of erythrocyte and skin fibroblast prolidase activity in Italian patients. Haematologica 1994; 79:13-18.
3. Liu G, Nakayama K, Awata S, Tang S, Kitaoka N, Manabe M, et al. Prolidase isoenzymes in the rat: their organ distribution, developmental change and specific inhibitors. Pediatr Res 2007; 62:54-59.
4. Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A. Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. Clin Chem 1984; 30:211-215.
5. Erbagci AB, Araz M, Erbagci A, Tarakcioglu M, Namiduru ES. Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin Biochem 2002; 35:263-268.
6. Altindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int 2007; 27:339-344.
7. Gejyo F, Kishore BK, Arakawa M. Prolidase and prolinase activities in the erythrocytes of patients with chronic uremia. Nephron 1983; 35:58-61.
8. Demirbag R, Yildiz A, Gur M, Yilmaz R, Elci K, Aksoy N. Serum prolidase activity in patients with hypertension and its relation with left ventricular hypertrophy. Clin Biochem 2007; 40:1020-1025.
9. Lijnen HR. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003-2004; 33:275-281.
10. Ye S, Humphries S, Henney A. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin Sci (Lond) 1998; 94:103-110.
11. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004; 6:112-120.
12. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51:606-607.
13. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: application to imminodipeptiduria. Clin Chim Acta 1982; 125:193-205.
14. Chinard FP. Photometric estimation of proline and ornithine. J Biol Chem 1952; 199:91-95.
15. Arab K, Steghens JP. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem 2004; 325:158-163.
16. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
17. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993; 121:257-262.
18. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
19. Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005; 35: 331-335.
20. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ III, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97:1708-1715.
21. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005; 96:339-345.
22. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 2005; 69: 1035-1040.
23. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Levels of matrix metalloproteinase-1 in patients with and without coronary artery disease and relation to complex and noncomplex coronary plaques. Am J Cardiol 2005; 95:90-92.
24. Beaudeux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003; 169:139-146.
25. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141:211-217.
26. Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 2005; 35:537-545.
27. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151:1101.e1-1101.e8.
28. Lubos E, Schnabel R, Rupprecht HJ, Bickel C, Messow CM, Prigge S, et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 2006; 27:150-156.
29. Jones GT, Kay IP, Chu JW, Wilkins GT, Phillips LV, McCormick M, et al. Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 2006; 26:e121-e125.
30. Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 1998; 3:199-206.
31. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol 1994; 89:59-70.
32. Surazynski A, Palka J, Wolczynski S. Phosphorylation of prolidase increases the enzyme activity. Mol Cell Biochem 2001; 220:95-101.
33. Surazynski A, Sienkiewicz P, Wolczynski S, Palka J. Differential effects of echistatin and thrombin on collagen production and prolidase activity in human dermal fibroblasts and their possible implication in beta1-integrin- mediated signaling. Pharmacol Res 2005; 51:217-221.
34. Aslan M, Nazligul Y, Horoz M, Bolukbas C, Bolukbas FF, Aksoy N, et al. Serum prolidase activity and oxidative status in Helicobacter pylori infection. Clin Biochem 2007; 40:37-40.
35. Cechowska-Pasko M, Palka J, Wojtukiewicz MZ. Enhanced prolidase activity and decreased collagen content in breast cancer tissue. Int J Exp Pathol 2006; 87:289-296.
36. Senboshi Y, Oono T, Arata J. Localization of prolidase gene expression in scar tissue using in situ hybridization. J Dermatol Sci 1996; 12:163-171.
37. Duong HS, Zhang QZ, Le AD, Kelly AP, Kamdar R, Messadi DV. Elevated prolidase activity in keloids: correlation with type I collagen turnover. Br J Dermatol 2006; 154:820-828.
38. Shrinath M, Walter JH, Haeney M, Couriel JM, Lewis MA, Herrick AL. Prolidase deficiency and systemic lupus erythematosus. Arch Dis Child 1997; 76:441-444.
39. Evrenkaya TR, Atasoyu EM, Kara M, Unver S, Gultepe M. The role of prolidase activity in the diagnosis of uremic bone disease. Ren Fail 2006; 28:271-274.
40. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998; 39:1529-1542.
41. Gur M, Aslan M, Yildiz A, Demirbag R, Yilmaz R, Selek S, et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006; 36:779-787.